Department of Rheumatology, Municipal Hospital in Olsztyn, 10-900 Olsztyn, Poland.
Department of Pathophysiology, Faculty of Medicine, University of Warmia and Mazury, 10-900 Olsztyn, Poland.
Int J Mol Sci. 2017 Dec 28;19(1):80. doi: 10.3390/ijms19010080.
Considerable progress has been made recently in understanding the complex pathogenesis and treatment of spondyloarthropathies (SpA). Currently, along with traditional disease modifying anti-rheumatic drugs (DMARDs), TNF-α, IL-12/23 and IL-17 are available for treatment of such diseases as ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Although they adequately control inflammatory symptoms, they do not affect the abnormal bone formation processes associated with SpA. However, the traditional therapeutic approach does not cover the regenerative treatment of damaged tissues. In this regards, stem cells may offer a promising, safe and effective therapeutic option. The aim of this paper is to present the role of mesenchymal stromal cells (MSC) in pathogenesis of SpA and to highlight the opportunities for using stem cells in regenerative processes and in the treatment of inflammatory changes in articular structures.
近年来，人们在理解脊柱关节炎（SpA）的复杂发病机制和治疗方面取得了相当大的进展。目前，除了传统的疾病修饰抗风湿药物（DMARDs）外，TNF-α、IL-12/23 和 IL-17 也可用于治疗强直性脊柱炎（AS）和银屑病关节炎（PsA）等疾病。虽然它们可以充分控制炎症症状，但它们不能影响与 SpA 相关的异常骨形成过程。然而，传统的治疗方法并不包括对受损组织的再生治疗。在这方面，干细胞可能提供一种有前途、安全有效的治疗选择。本文的目的是介绍间充质基质细胞（MSC）在 SpA 发病机制中的作用，并强调干细胞在再生过程中和治疗关节结构炎症变化中的应用机会。
